Irma Egoavil – Country Manager, Celgene Mexico
Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the…
Celgene is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, and ISTODAX. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs® compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to our leading oral anti-inflammatory agents and cellular therapies. We believe our commercial stage products and the depth of our product pipeline, provide the catalysts for future growth.
Contact details
Celgene México
Juan Salvador Agraz 65, Piso 17,
Colonia Lomas de Santa Fe.
C.P. 05300. México, D.F.
MEXICO
Tel: +52 (55) 41236700
Website: www.celgene.com
Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the…
Two companies from two different countries chose Mexico as their entry market to Latin America. The heads of these companies spoke to PharmaBoardroom about their market entry strategies. Edmée Stenken,…
The industry of medical devices is soaring in Mexico. The general manager of ConvaTec discusses strategic priorities, new approaches and how reduced time to market is feeding the double-digit growth…
IMS Health recently released its World Review 2015. The new general manager of North Latin America shares the company’s assessment on the performance of the Mexican pharmaceutical market for 2014,…
The industry of medical devices is still not very well understood. Pablo Dávila shared with us his overview on the Mexican market, how the Mexican Association of Innovative Medical Device…
The technical & RA director and the managing director of Qually Corporacion explain how authorized third partied act as an extension of the regulative body, Cofepris, helping to assure that…
The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15…
Claudio Soto, general manager of PAREXEL Mexico, discusses how the clinical research process required to receive approval for a new clinical protocol in Mexico is fairly straightforward compared to other…
The pharmaceutical and medical devices industries are both classified as emerging sectors by the Ministry of Economy. The undersecretary of industry and commerce discusses the importance of the sectors to…
In public health everything is a priority. The Undersecretary of Prevention and Health Promotion explains how Mexico’s Ministry of Health is handling the country’s changing epidemiological profile without forgetting communicable…
The implementation of third authorized parties has been a very proactive effort implemented by Mexico’s regulatory authority Cofepris to expedite the time to issue sanitary registrations. The CEO of Entimem…
Starting a new business is no easy task. The general manager of Alliance SFA shares his experience, how he decided to focus on second-tier and niche players to offer tailor-made…
Founded back in 1956, Laboratorios Keton is a small 100 percent Mexican company committed to provide high-quality contract manufacturing services to local as well as international drug makers. With more…
See our Cookie Privacy Policy Here
